Prolong Pharmaceuticals

Prolong Pharmaceuticals is a biopharmaceutical company established in 2005 and headquartered in New Jersey, United States. The company's slogan is to provide innovative biopharmaceutical products addressing critical health conditions and specialized manufacturing solutions for the pharmaceutical industry. Prolong Pharmaceuticals is focused on developing and marketing a range of biopharmaceutical products, including PEG-uricase for hyperuricemia treatment, PEG-arginase for addressing melanoma and hepatocellular carcinoma, PEG-protein for managing hypovolemic shock, PEG-peptide antibiotic for staphylococcus infections, and PEG-streptokinase for myocardial infarctions. They also offer anti-cancer agents and Erythropoietin for treating anemia. Additionally, the company provides custom manufacturing services and licenses its products to pharmaceutical companies. The most recent significant investment in Prolong Pharmaceuticals was a $30.00M Venture Round investment on 14 October 2010. The details of the investors involved in this round are not available at this time. Prolong Pharmaceuticals operates in the Biopharma, Biotechnology, and Pharmaceutical industries, aiming to offer solutions to critical health conditions through its diverse product portfolio and custom manufacturing services. With its focus on innovation and addressing unmet medical needs, Prolong Pharmaceuticals presents itself as a promising prospect for venture capital investment within the pharmaceutical sector.